Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

MSCL.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Satellos Bioscience Inc.TSX: MSCL.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows 13.2% year over year

Q1 FY2026 stock-based compensation of $727K rose 13.2% year over year. Sequentially, it fell 26.2% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$727K-26.2% QoQ
Last fiscal yearDec 2025
$3.24M+53.1% YoY
LTMMar 2026
$3.32M— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.2%——
1 year+53.1%——
3-year CAGR+31.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

Mixed currencies · from the cash flow

Latest · FY2025
3.24M USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How MSCL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +31.0% compares with a peer median of -1.8%.
MSCL.TO Competitors
Stock-Based Compensation for MSCL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$11.4M CAD-21.5%+28.8%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$3.32M USD—+31.0%—
SVA.TOSernova Corp.LTM Apr 2026CA$2.06M CAD+51.2%-32.4%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD-100.0%——
Peer median (excluding MSCL.TO) —-21.5%-1.8%—

Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Net Income(15.51M)(11.32M)(15.89M)(28.1M)(25.31M)
Depreciation & Amortization165.69K337K7K20K4K
Deferred Income Tax00000
Stock-Based Compensation971.53K1.44M2.17M2.11M3.24M
Change in Working Capital(485.64K)991K369K(1.03M)(1.5M)
Accounts Receivables(67.4K)267.55K(323K)(43K)66.14K
Inventory00000
Accounts Payables(390.47K)726.11K000
Other Working Capital(27.77K)(1.93K)692K(982K)(1.57M)
Other Non-Cash Items9.82M2.91M(1.07M)2.02M(435.77K)
Operating Cash Flow(5.03M)(5.78M)(14.5M)(24.98M)(24.01M)
Capital Expenditures(7.25K)(3K)(18K)(6K)(6.1K)
Acquisitions (Net)1.75M0000
Purchases of Investments00(17.52M)(37.34M)(23.78M)
Sales of Investments00043.68M14.2M
Other Investing Activities00000
Investing Cash Flow1.74M(3K)(17.54M)6.34M(9.58M)
Debt Repayment186.57K0(284K)00
Common Stock Issued7.08M2.78M32.46M42.8M2.28M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities185.46K018.85M10.68M0
Financing Cash Flow7.45M2.78M51.03M53.49M2.28M
Effect of Forex Changes(1.44K)(76K)1.15M744K(890.45K)
Net Change in Cash4.15M(2.95M)20.14M35.59M(32.2M)
Free Cash Flow(5.04M)(5.79M)(14.52M)(24.98M)(24.02M)

Satellos Bioscience Inc.

TSX:MSCL.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.